Leap Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2011)

Organization Overview

First Clinical Trial
2011
NCT01239134
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Leap Therapeutics | Leap Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Bile Duct Neoplasms (Phase 1)

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinosarcoma (Phase 2)

Cholangiocarcinoma (Phase 1)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1)

Lung Neoplasms (Phase 1)

Melanoma (Phase 1)

Mixed Tumor, Mullerian (Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 18
  • # of Trial APIs: 21